IDH1 and acute myeloid leukemia: Further, a pooled analysis of data from clinical trials confirmed that patients with IDH1/2 wild-type acute myeloid leukemia (AML) and subjected to treatment with Ven + 5-Aza exhibited less favorable results when presenting with poor-risk cytogenetics in comparison to their counterparts with IDH1/2 mutations.